Codexis, Inc. (NASDAQ: CDXS), a developer of world-leading enzymes and processes for the production of pharmaceuticals, biofuels and bio-based chemicals, announced today that it will exhibit the Company’s enzymatic approaches for the fine chemicals industry at the Informex USA 2013 Conference, being held at the Anaheim Convention Center in Anaheim, Calif., from February 19-22, 2013.
The Company will use the opportunity to discuss its technology breakthroughs that enable enzymatic processes to achieve greater cost savings and speed to market for a variety of fine and specialty chemicals.
“Codexis continues to show that its unique and differentiated enzymatic approach allows for exciting opportunities across the pharmaceutical and chemical fields,” said John Nicols, President and CEO of Codexis. “Our advanced enzymatic processes allow for more efficient production than traditional chemistry approaches. We look forward to further demonstrating the large impact of our technology platform and are highly focused on accelerating the adoption of our enzymatic approach through partnerships among leading players in the fine chemicals industry.”
Codexis’ exhibit at the conference will be located in Booth 2423H of the Green Exchange Gallery at the Anaheim Convention Center from February 19-22, 2013.
About Codexis, Inc.
Codexis, Inc. is a developer of world-leading enzymes and processes for the production of pharmaceuticals, biofuels and bio-based chemicals. Codexis' product lines include CodeXyme® cellulase enzymes and CodeXol™ detergent alcohol. Partners and customers include global leaders such as Merck, Pfizer and Arch Pharmalabs. For more information, see
Forward Looking Statements
This press release contains forward-looking statements relating to potential commercial opportunities for Codexis’ technologies in the pharmaceutical and fine chemicals fields. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond our control and could materially affect actual results. Factors that could materially affect actual results include our dependence on a limited number of products in our pharmaceutical business; potential adverse affects to our business if our customers’ pharmaceutical products are not received well in the markets; and our ability to develop and commercialize new products for the pharmaceutical market. Additional factors that could materially affect actual results can be found in Codexis’ Quarterly Report on Form 10-Q for the period ended September 30, 2012 filed with the Securities and Exchange Commission on November 7, 2012, including under the caption “Risk Factors.” Codexis expressly disclaims any intent or obligations to update these forward-looking statements, except as required by law.